 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 GLOBE NEWSWIRE -- InspirMed Inc., a subsidiary of TLC Nasdaq: TLC, TWO: 4152 that specializes in the development of inhalable liposome formulation programs, announced today that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine ISAM Congress. 